Literature DB >> 8689818

The effects of the menstrual cycle, race, and gender on adrenergic receptors and agonists.

P J Mills1, M G Ziegler, R A Nelesen, B P Kennedy.   

Abstract

OBJECTIVE: To examine possible effects of race, sex, and the menstrual cycle on adrenergic receptors (beta 2 and alpha 2) and agonists.
METHODS: Sixty-three normotensive black men and women and white men and women were studied twice, approximately 6 weeks apart. Women were studied once during the follicular phase and once during the luteal phase of the menstrual cycle. beta 2-Adrenergic receptors and adenylate cyclase activity were examined on lymphocytes, and alpha 2-adrenergic receptors were examined on platelets. Norepinephrine and epinephrine were determined in plasma.
RESULTS: Women showed greater lymphocyte beta 2-receptor sensitivity (isoproterenol-stimulated cyclic adenosine monophosphate; p = 0.009). Women also showed greater postreceptor adenylate cycle activity independent of the beta-receptor (forskolin stimulation; p = 0.006). When these differences were controlled for, the gender-related differences in beta 2-receptor sensitivity were no longer evident. Black women had a reduced beta 2-receptor sensitivity in the luteal phase compared with the follicular phase, whereas white women showed no significant change (p = 0.018). Black subjects had lower lymphocyte beta 2-receptor density (Bmax) values than white subjects (p = 0.047). There were no significant effects on alpha 2-adrenergic receptors.
CONCLUSION: The findings suggest that although there is no generalized effect of the menstrual cycle on adrenergic receptors in white women, such an effect may occur in black women. The findings also suggest that previously reported gender-related differences in beta 2-receptor sensitivity may be due to gender-related differences in postreceptor activity and not the beta 2-receptor per se.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8689818     DOI: 10.1016/S0009-9236(96)90172-1

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  G-protein-coupled receptor kinase activity is increased in hypertension.

Authors:  R Gros; J L Benovic; C M Tan; R D Feldman
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

2.  Race and sex differences in cardiovascular α-adrenergic and β-adrenergic receptor responsiveness in men and women with high blood pressure.

Authors:  Andrew Sherwood; LaBarron K Hill; James A Blumenthal; Kristy S Johnson; Alan L Hinderliter
Journal:  J Hypertens       Date:  2017-05       Impact factor: 4.844

3.  Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma.

Authors:  Edwin W Lai; Shiromi M Perera; Bas Havekes; Henri J L M Timmers; Frederieke M Brouwers; Beverly McElroy; Karen T Adams; Shoichiro Ohta; Robert A Wesley; Graeme Eisenhofer; Karel Pacak
Journal:  Endocrine       Date:  2008-11-04       Impact factor: 3.633

Review 4.  Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women.

Authors:  Flavia Franconi; Ilaria Campesi
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

5.  Estrous cycle-dependent neurovascular dysfunction induced by angiotensin II in the mouse neocortex.

Authors:  Carmen Capone; Josef Anrather; Teresa A Milner; Costantino Iadecola
Journal:  Hypertension       Date:  2009-06-08       Impact factor: 10.190

6.  beta(2)-Adrenergic receptor-dependent sexual dimorphism for murine leukocyte migration.

Authors:  Catherine de Coupade; Adrienne S Brown; Paul F Dazin; Jon D Levine; Paul G Green
Journal:  J Neuroimmunol       Date:  2007-04-18       Impact factor: 3.478

7.  Effect of propranolol on sympathetically mediated leg vasoconstriction in humans.

Authors:  Thomas K Pellinger; John R Halliwill
Journal:  J Physiol       Date:  2007-07-12       Impact factor: 5.182

8.  Renin angiotensin system and gender differences in dopaminergic degeneration.

Authors:  Ana I Rodriguez-Perez; Rita Valenzuela; Belen Joglar; Pablo Garrido-Gil; Maria J Guerra; Jose L Labandeira-Garcia
Journal:  Mol Neurodegener       Date:  2011-08-16       Impact factor: 14.195

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.